Loading...
Loading...
EGRX| Name | Value |
|---|---|
| Revenues | 60.7M |
| Cost of Revenue | 19.9M |
| Gross Profit | 40.8M |
| Operating Expense | 31.4M |
| Operating I/L | 9.5M |
| Other Income/Expense | 3.8M |
| Interest Income | 0.3M |
| Pretax | 13.3M |
| Income Tax Expense | 5.1M |
| Net Income/Loss | 8.2M |
Eagle Pharmaceuticals, Inc. is a pharmaceutical company specializing in developing and commercializing product candidates for the treatment of central nervous system diseases, metabolic critical care, and oncology. The company's product portfolio includes Ryanodex for malignant hyperthermia, Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma, as well as other product candidates such as EP-4104, PEMFEXY, EA-114, and Vasopressin injection. Eagle Pharmaceuticals generates revenue through the sale of these pharmaceutical products and through license and collaboration agreements with other pharmaceutical companies for the development and commercialization of additional therapeutic products.
